title: A perspective on molecular genetic studies of tardive dyskinesia: one clue for individualized antipsychotic drug therapy.
abstract: Interindividual genetic profile differences related to antipsychotic drug therapy may be determined based on molecular genetic studies of the pathogenesis of schizophrenia and studies of antipsychotic drug responses (therapeutic as well as adverse responses). In the present article, we review molecular genetic studies of tardive dyskinesia (TD), which is a representative adverse response to antipsychotic drugs. Such studies have been performed to explore the gene-associated pharmacokinetic and pharmacodynamic processes of antipsychotic drugs. Positive associations between several genes and TD have been reported. The accumulation of results from such studies will hopefully lead to individualized antipsychotic drug therapies that involve the application of new genomic techniques, including DNA microarrays. Subsequently, antipsychotic drugs may in the future be prescribed for smaller subgroups of patients who have been classified as having a particular genetic profile.
authors.affiliation: Department of Psychiatry, School of Medicine, University of Occupational and Environmental Health, Yahatanishi-ku, Kitakyushu, 807-8555, Japan. o-ohmori@med.uoeh-u.ac.jp
authors.forename: Osamu
authors.initials: O
authors.lastname: Ohmori
authors.forename: Takahiro
authors.initials: T
authors.lastname: Shinkai
authors.forename: Hiroko
authors.initials: H
authors.lastname: Hori
authors.forename: Chima
authors.initials: C
authors.lastname: Matsumoto
authors.forename: Jun
authors.initials: J
authors.lastname: Nakamura
mesh_terms: D014150:Antipsychotic Agents / Q000493:pharmacokinetics* / Q000494:pharmacology*; D020820:Dyskinesias / Q000188:drug therapy* / Q000235:genetics*; D006801:Humans; D020411:Oligonucleotide Array Sequence Analysis; D010347:Patient Care Planning
chemical_list: D014150:Antipsychotic Agents